Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab.
Abstract
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab.
참고문헌 (7)
- Horwitz SM, "NCCN guidelines insights: non-hodgkin's lymphomas, version 3.2016", J Natl Compr Canc Netw, 14, pp.1067~1079 (2016)
- Armand P, "Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure", J Clin Oncol (2016)[DOI]
- Chan TS, "Low-dose pembrolizumab for relapsed", refractory hodgkin lymphoma: high efficacy with minimal toxicity, 2017, pp.96, 647~651
- Hodi FS, "Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab", J Clin Oncol, 34, pp.1510~1517 (2016)
- Di Giacomo AM, "Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases", Cancer Immunol Immunother, 58, pp.1297~1306 (2009)
- Wolchok JD, "Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria", Clin Cancer Res, 15, pp.7412~7420 (2009)
- Seymour L, "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", Lancet Oncol, 18, pp.e143~e152 (2017)